Abstract 5627
Background
Inducible T cell Co-Stimulator (ICOS) is a co-stimulatory receptor, induced on activated T cells (TC) upon TC receptor engagement. Emerging clinical and preclinical data for checkpoint inhibitors demonstrate increased ICOS expression on effector TC, which has been linked to improved clinical outcomes. We have therefore developed an ICOS antibody optimized for agonist activity.
Methods
Syngeneic mouse tumor models and human ex-vivo PBMC and tumor infiltrating lymphocyte culture assays were utilized to evaluate the activity of a murine (7E.17G9) or human (H2L5) specific ICOS agonist antibody alone and in combination with PD-1 blockade. A selection of flow cytometry, IHC, multiplex IF, nanostring, and in silico analysis was performed to characterize and develop H2L5 for subsequent clinical evaluation.
Results
ICOS induction either with 7E.17G9 or H2L5 agonist antibody induced significant activation and clonal expansion of both CD4+ and CD8+ effector TC. These TC had increased effector function (higher IFN-γ and Granzyme B) and increased homing to tumors resulting in antitumor responses when administered alone and in combination with PD-1 blockade. The level of expression of ICOS on effector and regulatory TC was found to overlap, suggesting that Fc-mediated depletion associated with IgG1 may result in depletion of effector TC. Preclinical data using different Fc isotypes supported the selection of the stabilized IgG4PE isotype for optimal agonism in the absence of NK-mediated depletion of effector TC. Drug concentrations associated with ICOS receptor occupancy, increases in TC activation and tumor reduction, support selected doses and biomarker strategy in the clinic. Select solid tumors types were identified for clinical studies based on expression of ICOS, ICOS-L, PD-L1 and PD-1.
Conclusions
IgG4PE provides the optimal isotype for delivering ICOS agonism whilst reducing the risk of depletion of ICOS positive effector TC. The comprehensive preclinical data package generated, supports clinical testing of the H2L5 IgG4PE ICOS agonist antibody (GSK3359609), currently being investigated alone and in combination with pembrolizumab, in a first in human clinical study (INDUCE-1).
Clinical trial identification
Legal entity responsible for the study
GlaxosmithKline.
Funding
GlaxoSmithKline.
Editorial Acknowledgement
Disclosure
S. Brett, S. Yadavilli, L. Seestaller-Wehr, S. Bhattacharya, H. Jackson, M. Bi, T. Zhang, Y.K. Katlinskaya, H. Shi, J. Jing, A. Hahn, S. Speller, D. David Figueroa, J. Yu, A. Hoos: Employee and stockholder: Glaxosmithkline Pharmaceuticals. D. Olive: Cofounder and shareholder: Imcheck Therapeutics. M. Cragg: Consultant: Bioinvent; Educational and advisory roles: Baxalta; Research funding: Roche, Bioinvent, Gilead, GSK. P. Mayes: Stockholder and employee: Incyte. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract